Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
HealthDay News — Youth receiving antipsychotic treatment have adverse changes in adiposity and insulin sensitivity, with the greatest fat increases seen with olanzapine, according to a study published online June 13 in JAMA Psychiatry.
Ginger E. Nicol, MD, from the Washington University School of Medicine in St. Louis, and colleagues recruited antipsychotic-naive youths aged 6 to 18 years who were diagnosed with 1 or more psychiatric disorders and clinically significant aggression and in whom antipsychotic treatment was considered. Participants were randomized to 1 of 3 antipsychotics commonly used in children with disruptive behavioral disorders — oral aripiprazole (49 patients), olanzapine (46 patients), or risperidone (49 patients) — and were evaluated for 12 weeks.
Overall, 29.9% of participants were overweight or obese at baseline. The researchers found that from baseline to week 12, the dual-energy X-ray absorptiometry percentage total body fat increased by 1.18, 4.12, and 1.66% for risperidone, olanzapine, and aripiprazole, respectively, and was significantly greater for olanzapine than risperidone or aripiprazole. Insulin-stimulated change in glucose rate of disappearance increased by 2.3% for risperidone from baseline to week 12 and decreased by 29.34 and 30.26% for olanzapine and aripiprazole, respectively; the difference across medications was not significant. In the pooled study sample, there was a significant decrease in the primary measure of insulin sensitivity during 12 weeks.
“The results inform risk-benefit considerations for antipsychotic use in youths,” the authors write.
Two authors disclosed financial ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
